Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), has announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells. The patent will be issued on August 2, 2017.
This therapeutic-focused patent follows previous intellectual property that Cellectis has obtained over the two last decades for major gene editing technologies including meganucleases, TALEN, MegaTAL and CRISPR.
“Cellectis is a pioneering gene editing company that has always been at the forefront of all gene editing technologies,” said Dr. André Choulika, Cellectis chairman & chief executive officer. “We have been the first to explore the potential of CRISPR in its early days in various applications, including therapeutics and food, and these early findings ultimately led to the grant of this new patent. While Cellectis has selected TALEN as the most robust and adaptable technology for human therapeutic use and for the Company’s product pipeline, our team does sometimes use CRISPR-based nucleases for T-cell research, as it is a less-expensive option and convenient for gene discovery purposes. As such, this patent only further reinforces Cellectis’ leadership position in the gene editing industry, with more patents coming down the pike for the Company in the near future.”
Convinced of its strong value for future development of engineered CAR T-cells, Cellectis will make this patent available for licensing to companies that are willing to use this technology in T-cells.
The inventors of this patent are Dr. André Choulika, chairman & chief executive officer of Cellectis and one of the pioneers in the development of nuclease-based genome editing technologies; Dr. Philippe Duchateau, Cellectis Chief Scientific Officer and seasoned gene editing expert and Dr. Laurent Poirot, Cellectis Head of Early Discovery and expert of gene functions in immune cells.